D Rupasinghe1, S Kiertiburanakul2, A Kamarulzaman3, F Zhang4, N Kumarasamy5, R Chaiwarith6, T P Merati7, C D Do8, S Khusuwan9, A Avihingsanon10, M P Lee11, P S Ly12, E Yunihastuti13, K V Nguyen14, R Ditangco15, Y J Chan16, S Pujari17, O T Ng18, J Y Choi19, Blh Sim20, J Tanuma21, S Sangle22, J Ross23, M Law1. 1. The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia. 2. Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. 3. University Malaya Medical Centre, Kuala Lumpur, Malaysia. 4. Beijing Ditan Hospital, Capital Medical University, Beijing, China. 5. CART CRS, Voluntary Health Services, Chennai, India. 6. Research Institute for Health Sciences, Chiang Mai, Thailand. 7. Faculty of Medicine Udayana University & Sanglah Hospital, Bali, Indonesia. 8. Bach Mai Hospital, Hanoi, Vietnam. 9. Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand. 10. HIV-NAT/Thai Red Cross AIDS Research Centre, Bangkok, Thailand. 11. Queen Elizabeth Hospital, Hong Kong SAR, China. 12. National Center for HIV/AIDS, Dermatology & STDs, Phnom Penh, Cambodia. 13. Faculty of Medicine Universitas Indonesia, Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia. 14. National Hospital for Tropical Diseases, Hanoi, Vietnam. 15. Research Institute for Tropical Medicine, Muntinlupa City, Philippines. 16. Taipei Veterans General Hospital, Taipei, Taiwan. 17. Institute of Infectious Diseases, Pune, India. 18. Tan Tock Seng Hospital, Singapore City, Singapore. 19. Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea. 20. Hospital Sungai Buloh, Sungai Buloh, Malaysia. 21. National Center for Global Health and Medicine, Tokyo, Japan. 22. BJ Government Medical College and Sassoon General Hospitals, Pune, India. 23. TREAT Asia, amfAR-The Foundation for AIDS Research, Bangkok, Thailand.
Abstract
OBJECTIVES: Early mortality among those still initiating antiretroviral therapy (ART) with advanced stages of HIV infection in resource-limited settings remains high despite recommendations for universal HIV treatment. We investigated risk factors associated with early mortality in people living with HIV (PLHIV) starting ART at low CD4 levels in the Asia-Pacific. METHODS: PLHIV enrolled in the Therapeutics, Research, Education and AIDS Training in Asia (TREAT Asia) HIV Observational Database (TAHOD) who initiated ART with a CD4 count < 100 cells/μL between 2003 and 2018 were included in the study. Early mortality was defined as death within 1 year of ART initiation. PLHIV in follow-up for > 1 year were censored at 12 months. Competing risk regression was used to analyse risk factors with loss to follow-up as a competing risk. RESULTS: A total of 1813 PLHIV were included in the study, of whom 74% were male. With 73 (4%) deaths, the overall first-year mortality rate was 4.27 per 100 person-years (PY). Thirty-eight deaths (52%) were AIDS-related, 10 (14%) were immune reconstituted inflammatory syndrome (IRIS)-related, 13 (18%) were non-AIDS-related and 12 (16%) had an unknown cause. Risk factors included having a body mass index (BMI) < 18.5 [sub-hazard ratio (SHR) 2.91; 95% confidence interval (CI) 1.60-5.32] compared to BMI 18.5-24.9, and alanine aminotransferase (ALT) ≥ 5 times its upper limit of normal (ULN) (SHR 6.14; 95% CI 1.62-23.20) compared to ALT < 5 times its ULN. A higher CD4 count (51-100 cells/μL: SHR 0.28; 95% CI 0.14-0.55; and > 100 cells/μL: SHR 0.12; 95% CI 0.05-0.26) was associated with reduced hazard for mortality compared to CD4 count ≤ 25 cells/μL. CONCLUSIONS: Fifty-two per cent of early deaths were AIDS-related. Efforts to initiate ART at CD4 counts > 50 cell/μL are associated with improved short-term survival rates, even in those with late stages of HIV disease.
OBJECTIVES: Early mortality among those still initiating antiretroviral therapy (ART) with advanced stages of HIV infection in resource-limited settings remains high despite recommendations for universal HIV treatment. We investigated risk factors associated with early mortality in people living with HIV (PLHIV) starting ART at low CD4 levels in the Asia-Pacific. METHODS: PLHIV enrolled in the Therapeutics, Research, Education and AIDS Training in Asia (TREAT Asia) HIV Observational Database (TAHOD) who initiated ART with a CD4 count < 100 cells/μL between 2003 and 2018 were included in the study. Early mortality was defined as death within 1 year of ART initiation. PLHIV in follow-up for > 1 year were censored at 12 months. Competing risk regression was used to analyse risk factors with loss to follow-up as a competing risk. RESULTS: A total of 1813 PLHIV were included in the study, of whom 74% were male. With 73 (4%) deaths, the overall first-year mortality rate was 4.27 per 100 person-years (PY). Thirty-eight deaths (52%) were AIDS-related, 10 (14%) were immune reconstituted inflammatory syndrome (IRIS)-related, 13 (18%) were non-AIDS-related and 12 (16%) had an unknown cause. Risk factors included having a body mass index (BMI) < 18.5 [sub-hazard ratio (SHR) 2.91; 95% confidence interval (CI) 1.60-5.32] compared to BMI 18.5-24.9, and alanine aminotransferase (ALT) ≥ 5 times its upper limit of normal (ULN) (SHR 6.14; 95% CI 1.62-23.20) compared to ALT < 5 times its ULN. A higher CD4 count (51-100 cells/μL: SHR 0.28; 95% CI 0.14-0.55; and > 100 cells/μL: SHR 0.12; 95% CI 0.05-0.26) was associated with reduced hazard for mortality compared to CD4 count ≤ 25 cells/μL. CONCLUSIONS: Fifty-two per cent of early deaths were AIDS-related. Efforts to initiate ART at CD4 counts > 50 cell/μL are associated with improved short-term survival rates, even in those with late stages of HIV disease.
Authors: Nicole L De La Mata; Penh S Ly; Oon T Ng; Kinh V Nguyen; Tuti P Merati; Thuy T Pham; Man P Lee; Jun Y Choi; Annette H Sohn; Matthew G Law; Nagalingeswaran Kumarasamy Journal: Int J STD AIDS Date: 2017-03-21 Impact factor: 1.359
Authors: V Saraceni; B S King; S C Cavalcante; J E Golub; L M Lauria; L H Moulton; R E Chaisson; B Durovni Journal: Int J Tuberc Lung Dis Date: 2008-07 Impact factor: 2.373
Authors: Jialun Zhou; N Kumarasamy; Rossana Ditangco; Adeeba Kamarulzaman; Christopher K C Lee; Patrick C K Li; Nicholas I Paton; Praphan Phanuphak; Sanjay Pujari; Asda Vibhagool; Wing-Wai Wong; Fujie Zhang; John Chuah; Kevin R Frost; David A Cooper; Matthew G Law Journal: J Acquir Immune Defic Syndr Date: 2005-02-01 Impact factor: 3.771
Authors: Samuel W Reinhardt; Andrej Spec; Johanna Meléndez; Andrea Alonzo Cordon; Ian Ross; William G Powderly; Carlos Mejia Villatoro Journal: Open Forum Infect Dis Date: 2017-12-30 Impact factor: 3.835
Authors: Abraham Siika; Leanne McCabe; Mutsa Bwakura-Dangarembizi; Cissy Kityo; Jane Mallewa; Jay Berkley; Kath Maitland; Anna Griffiths; Keith Baleeta; Shepherd Mudzingwa; James Abach; Kusum Nathoo; Margaret J Thomason; Andrew J Prendergast; Ann Sarah Walker; Diana M Gibb Journal: Clin Infect Dis Date: 2018-03-04 Impact factor: 9.079
Authors: Awachana Jiamsakul; Nagalingeswaran Kumarasamy; Rossana Ditangco; Patrick C K Li; Praphan Phanuphak; Thira Sirisanthana; Somnuek Sungkanuparph; Pacharee Kantipong; Christopher K C Lee; Mahiran Mustafa; Tuti Merati; Adeeba Kamarulzaman; Thida Singtoroj; Matthew Law Journal: J Int AIDS Soc Date: 2014-05-16 Impact factor: 5.396
Authors: Victor Ssempijja; Edith Namulema; Racheal Ankunda; Thomas C Quinn; Frank Cobelens; Anja Van't Hoog; Steven J Reynolds Journal: EClinicalMedicine Date: 2020-11-07
Authors: Victor Ssempijja; Gertrude Nakigozi; Robert Ssekubugu; Joseph Kagaayi; Godfrey Kigozi; Fred Nalugoda; Betty Nantume; James Batte; Grace Kigozi; Ping Teresa Yeh; Hadijja Nakawooya; David Serwadda; Thomas C Quinn; Ronald H Gray; Maria J Wawer; Kate M Grabowski; Larry W Chang; Anja Van't Hoog; Frank Cobelens; Steven J Reynolds Journal: J Acquir Immune Defic Syndr Date: 2022-03-08 Impact factor: 3.771